Amgen acquired Seattle-based Rodeo Therapeutics for a $55M upfront payment plus up to $666M in contingent milestone payments (total ~$721M). Rodeo's 15-PGDH program complements Amgen's inflammation portfolio and offers potential applications in tissue regeneration, colitis and IPF.